Objective/Hypothesis
The purpose of this review is to summarize evidence‐based data regarding the ototoxic effects of potential COVID‐19 therapeutics to treat patients suffering from SARS‐CoV‐2.
Methods
Medications under investigation as novel therapeutics to treat COVID‐19 were identified using the search term
coronavirus therapeutics
,
COVID therapeutics
, and
SARS‐CoV‐2 therapeutics
on
ClinicalTrials.gov
and the PubMed Database. A literature review was performed using the PubMed Database for each proposed COVID‐19 therapeutic to identify relevant articles. Search criteria included Medical Subject Headings (MeSH) and key word search terms for
ototoxicity
,
vestibulotoxicity
,
hearing disorders
, and
vertigo
.
Results
Six proposed COVID‐19 therapeutics were identified as possessing ototoxic side effects including chloroquine and hydroxychloroquine, azithromycin, lopinavir‐ritonavir, interferon, ribavirin, and ivermectin.
Conclusions
Available evidence suggests that ototoxic effects may be improved or mitigated by stopping the offending agent. Recognition of hearing loss, tinnitus, or imbalance/vertigo is therefore crucial to facilitate early intervention and prevent long‐term damage. Hospitals should consider the inclusion of audiologic monitoring protocols for patients receiving COVID‐19 therapeutics with known ototoxicity, especially in high‐risk patient groups such as the elderly and hearing impaired.
Laryngoscope
, 2021